Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp. - Seite 2

Giles Tilley, CEO of GenBio stated that, “We express confidence in the potential of our partnership (and pre-licensing arrangement) to develop the next generation of anti-inflammatory drugs as the health and wellness industry continues to transform. What we hope for is a line of organic and natural products that are effective and will truly help with health issues without the use of pharmaceuticals. These unfamiliar extracts are largely unknown in the U.S. market yet have been extensively studied in Australia and have already been subject to rigorous scientific evaluation and peer-reviewed publications. Some have also been brought to the U.S. for further review and as yet are under confidential research, with ground-breaking new discoveries as to their potential to advance human longevity.”

Overview of GenBio, Inc. (https://genbioinc.com/): GenBio, Inc. aims to create, through its IND Drug program, the next generation of anti-inflammatory drugs with the intention to disrupt the projected $191 billion+ anti-inflammatory drug market. GenBio, in addition, has access to a vast catalog of natural herbs, extracts, superfoods and functional food ingredients that can and will be formulated and licensed out to create a range of new nutraceuticals to aid in boosting the human immune system and promoting good health and longevity.

Overview of Strainsforpains, Inc.: Please visit our website at http://www.strainsforpains.com/. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company’s objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. The company owns a 7 acre facility in Pennsylvania that will be used for CBD product production. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/.

Safe Harbor Statement: Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Strainsforpains, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Strainsforpains, Inc. is unable to give any assurance that its expectations will be attained. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Strainsforpains, Inc.’s ability to control, and those actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Strainsforpains, Inc. filings with the Securities and Exchange Commission and OTC Markets.